MAD2L1 and breast carcinoma: Studies showed that MAD2L1 presented overexpression in breast cancer and was significantly associated with higher clinical stage, higher histological grade, aggressive tumors, and worse disease-free survival (Wang et al., 2015; Zhu et al., 2017).